Rosemont Pharmaceuticals
Our ambition has always been to support both patients with swallowing difficulties and the healthcare professionals who care for them. We are highly respected in the industry and have been instrumental in establishing best practice for the care of patients with swallowing difficulties. Rosemont advocate the use of liquid medication over manipulating solid dose medications and we have a range of educational materials designed for healthcare professionals which focuses on key patient groups and their medication management challenges.
Sygnature Discovery
Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services CRO. Founded in 2004 and private equity-backed since 2017, we operate a fully-enabled research facilities in Nottingham and Alderley Park, UK housing over 500 staff (80% of our scientists have PhDs). Our experienced R&D scientists possess all the professional skills and know-how required to undertake the most demanding of drug discovery and/or pre-clinical development projects and drive them from target validation, through hit identification, hit-to-lead and lead optimization to development candidate. Sygnature collaborates with its partners via risk share and FTE-based collaborations.
